Literature DB >> 36050519

Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy.

Wen-Lu Yan1,2, Tian-Qun Lang1,3, Wen-Hui Yuan1,2, Qi Yin4,5,6, Ya-Ping Li7,8,9,10.   

Abstract

Immunotherapy that activates immune systems for combating cancer has yielded considerable clinical benefits recently. However, the immunosuppressive tumor microenvironment (ITME) is a major hurdle to immunotherapy as it supports tumor to evade immune surveillance. Reversing ITME facilitates the recruitment and activation of antitumor immune cells, thereby promoting immunotherapy. Our group has developed various nanosized drug delivery systems (NDDSs) to modulate ITME with enhanced efficacy and safety. In the review we introduce the ITME-remodeling strategies for improving immunotherapy based on NDDSs including triggering tumor cells to undergo immunogenetic cell death (ICD), applying tumor vaccine, and directly regulating intratumoral immune components (immune cells or cytokines). In order to guide the design of NDDSs for amplified effects of antitumor immunotherapy, the contributions and future directions of this field are also discussed.
© 2022. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.

Entities:  

Keywords:  immunogenetic cell death (ICD); immunosuppressive tumor microenvironment (ITME); immunotherapy; nanosized drug delivery systems (NDDSs); tumor vaccine

Year:  2022        PMID: 36050519     DOI: 10.1038/s41401-022-00976-6

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  66 in total

1.  Is autoimmunity the Achilles' heel of cancer immunotherapy?

Authors:  Carl H June; Jeremy T Warshauer; Jeffrey A Bluestone
Journal:  Nat Med       Date:  2017-05-05       Impact factor: 53.440

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 3.  Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Robert Sidlow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

Review 4.  Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.

Authors:  Hathaichanok Phuengkham; Long Ren; Il Woo Shin; Yong Taik Lim
Journal:  Adv Mater       Date:  2019-02-18       Impact factor: 30.849

Review 5.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

6.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

Review 7.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cell       Date:  2018-10-04       Impact factor: 41.582

Review 8.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

Review 9.  Cancer immunoediting and resistance to T cell-based immunotherapy.

Authors:  Michele W L Teng; Mark J Smyth; Jake S O'Donnell
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

Review 10.  Role of the immunosuppressive microenvironment in immunotherapy.

Authors:  Garth W Tormoen; Marka R Crittenden; Michael J Gough
Journal:  Adv Radiat Oncol       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.